新华制药(000756) - 2020 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2020 was ¥1,705,982,914.01, representing a 4.67% increase compared to ¥1,617,765,684.10 in the same period last year[9] - Net profit attributable to shareholders was ¥86,286,544.27, up 13.40% from ¥75,444,841.65 in the previous year[9] - Basic and diluted earnings per share rose to ¥0.14, reflecting a 16.67% increase from ¥0.12 in the same period last year[9] - Operating profit for Q1 2020 was RMB 116,123,237.06, representing a growth of 14.22% year-on-year, while net profit attributable to shareholders was RMB 86,286,544.27, up 13.40%[26] - Total operating revenue for the current period reached ¥1,705,982,914.01, an increase of 4.3% compared to ¥1,629,794,138.89 in the previous period[60] - Net profit attributable to the parent company was ¥86,286,544.27, compared to ¥76,090,649.61 in the previous period, representing an increase of 13.9%[66] Cash Flow - The net cash flow from operating activities increased significantly by 92.92%, reaching ¥104,929,221.85 compared to ¥56,302,679.51 in Q1 2019[9] - The net cash flow from operating activities for Q1 2020 increased by RMB 50,538,947.48 to RMB 104,929,221.85, attributed to higher sales and improved inventory management[26] - The group reported a net cash inflow from financing activities of RMB 593,389,904.31 for Q1 2020, an increase of RMB 644,287,325.41 compared to the previous year, primarily from the loan received[28] - The financing activities generated a net cash inflow of CNY 593,389,904.31, a significant improvement from a net outflow of CNY 50,897,421.10 in the previous year[82] Assets and Liabilities - Total assets at the end of the reporting period were ¥7,044,298,293.98, a 9.45% increase from ¥6,436,024,609.48 at the end of the previous year[9] - The total current assets as of March 31, 2020, amounted to RMB 3,094,024,503.27, up from RMB 2,428,386,536.31 at the end of 2019, reflecting overall growth in asset base[42] - Current liabilities totaled CNY 2,481,572,789.63, slightly down from CNY 2,485,514,472.98, indicating a decrease of about 0.12%[48] - Total liabilities increased to ¥3,458,061,481.18 from ¥2,878,112,140.04, marking a rise of 20.1%[58] - Total liabilities increased to CNY 3,878,547,064.04 from CNY 3,325,495,154.66, reflecting a growth of about 16.58%[48] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 33,171[13] - The largest shareholder, Hualu Holdings Group Co., Ltd., held 32.94% of the shares, totaling 204,864,092 shares[14] - The company did not engage in any repurchase transactions during the reporting period[21] Research and Development - Research and development expenses for Q1 2020 totaled RMB 74,898,770.72, a 30.82% increase from the same period last year, reflecting ongoing investment in technological innovation[25] - Research and development expenses for the current period were ¥74,898,770.72, up from ¥57,253,929.71, reflecting a significant increase of 30.8%[63] Inventory Management - The group’s inventory decreased significantly, with a reduction of RMB 320,169,815.95 compared to the previous year, indicating effective inventory management[28] - Inventory decreased to CNY 408,642,300.70 from CNY 633,343,633.90, a decline of about 35.47%[52] Government Subsidies - The company received government subsidies amounting to ¥10,545,393.22 during the reporting period[9] - Other income for Q1 2020 rose to RMB 10,545,393.22, a significant increase of 129.91% year-on-year, mainly due to increased government subsidies received[25] Comprehensive Income - The total comprehensive income for the current period was ¥49,997,247.61, compared to ¥108,992,810.48 in the previous period, showing a decline of 54.1%[69] - The company reported a total comprehensive income of CNY 38,168,202.07 for the quarter, down from CNY 106,095,348.85 in the same quarter last year[76] Cash and Cash Equivalents - As of March 31, 2020, the group's cash and cash equivalents amounted to RMB 1,335,553,127.97, an increase of 93.43% compared to the beginning of the year, primarily due to a loan of RMB 600,000,000.00 from the controlling shareholder[24] - Cash and cash equivalents rose significantly to CNY 926,948,437.61 from CNY 298,770,314.96, marking an increase of about 210.67%[52] - Cash and cash equivalents at the end of the period totaled CNY 1,225,308,621.24, compared to CNY 544,958,241.71 at the end of the previous year, marking a significant increase[81] - The ending balance of cash and cash equivalents was 864,178,401.61 CNY, up from 263,157,976.78 CNY in the previous period[86] Other Financial Metrics - Long-term payables as of March 31, 2020, surged to RMB 650,155,284.74, a staggering increase of 1,192.90% due to the aforementioned loan from the controlling shareholder[25] - Long-term borrowings decreased to CNY 538,393,741.67 from CNY 589,779,008.96, a reduction of approximately 8.59%[48] - Total equity increased to CNY 3,165,751,229.94 from CNY 3,110,529,454.82, representing a growth of about 1.77%[51]